

# Direct Oral Anticoagulant Dosing for Stroke Prevention in People with Nonvalvular Atrial Fibrillation and Renal Impairment

Author: Dr Kevin Fernando, GP Partner, North Berwick Health Centre; Content Advisor, Medscape Global and UK | Email: kfernando@webmd.net

● No dose adjustment recommended ● Dose adjustment recommended ● Not recommended/contraindicated

	CrCl (ml/min)			
	≥50	30–49	15–29	<15
<b>Apixaban<sup>1</sup></b>	5 mg bd. Check ABC rule: <b>age</b> ≥80 years; <b>bodyweight</b> ≤60 kg; <b>creatinine</b> ≥133 mcml/l If ≥2 factors present, reduce dose to <b>2.5 mg bd</b>		2.5 mg bd	
<b>Dabigatran<sup>2</sup></b>	150 mg bd. Check: <b>age</b> ≥80 years and <b>drugs</b> : verapamil. If either present: <b>110 mg bd</b> If aged 75–80 years, CrCl 30–50 ml/min, GORD, or increased risk of bleeding, <b>consider</b> reduced dose of <b>110 mg bd</b>			
<b>Edoxaban<sup>3(A)</sup></b>	60 mg od. Check: <b>weight</b> ≤60 kg and <b>drugs</b> —cyclosporin, dronedarone, erythromycin, or ketoconazole If either present: <b>30 mg od</b>	30 mg od		
<b>Rivaroxaban<sup>4</sup></b>	20 mg od (take with or after food to increase bioavailability)	15 mg od (take with or after food to increase bioavailability)		

Table based on summaries of product characteristics and the author's clinical experience and appraisal of the literature.

[A] CrCl >80 ml/min: re-evaluate treatment choice and consider alternative. A trend towards decreasing efficacy with increasing CrCl has been observed, compared to well-managed warfarin with edoxaban.<sup>5</sup>

## Prescribing Notes

- An [MHRA drug safety update](#) published in 2023 re-emphasised that those on DOACs are at increased risk of bleeding, particularly older people with renal impairment. Specific DOAC reversal agents are available for dabigatran, apixaban, and rivaroxaban
- The Greater Glasgow and Clyde NHS Trust has published a blog titled, [Safe prescribing of direct oral anticoagulants \(DOACs\)](#), which includes signposting to a patient information booklet and alert card
- DOACs are not 'fire and forget' drugs;** renal and liver monitoring and assessment of concordance should be undertaken regularly. Frequency of monitoring and assessment will be dependent on individual patient characteristics, but should be at least **annual**<sup>5</sup>
- Useful rule of thumb: if CrCl is in the 30s, recheck CrCl 3-monthly; if CrCl is in the 20s, recheck CrCl 2-monthly, and so on. See the Specialist Pharmacy Service's [DOACs \(direct oral anticoagulation\) monitoring](#) for further advice regarding DOAC monitoring<sup>5</sup>
- Do not use eGFR** to assess the degree of renal impairment; eGFR was originally intended for the diagnosis and staging of CKD, whereas CrCl should be used for drug dosing, especially high-risk drugs or those with a narrow therapeutic index, such as DOACs
- CrCl is calculated automatically in many GP IT systems. There also online calculators (e.g. [QxMD](#)) and free apps (e.g. [MedCalX](#)). Use actual bodyweight from the last 12 months in these calculations (up to bodyweight

- 120 kg or BMI 40 kg/m<sup>2</sup>). Use adjusted bodyweight if individuals are above these thresholds.<sup>6</sup> See the Greater Glasgow and Clyde NHS Trust's [DOAC prescribing and body weight](#) blog for more information
- As with warfarin, patients on DOACs should carry patient alert cards supplied by the hospital, dispensing chemist, or GP practice. These are included within the [patient information materials](#) in each DOAC box
  - Healthcare professionals are advised to take caution when deciding to prescribe these anticoagulants to patients with other conditions, undergoing other procedures, and on other treatments, which may increase the risk of major bleeding. The following contraindications now apply to all new oral anticoagulants, for all indications and doses:
    - a lesion or condition, if considered a significant risk factor for major bleeding—see the sections on contraindications in the relevant summaries of product characteristics for further information
    - concomitant treatment with any other anticoagulant agent—see the sections on contraindications in the relevant summaries of product characteristics for further information
  - See also [Practical prescribing: direct oral anticoagulants](#), a useful article giving further practical advice; this article also discusses prescribing DOACs for the prevention and treatment of acute DVT and PE, thromboprophylaxis after elective knee/hip replacements, and the prevention of atherothrombotic events in adults with CAD or PAD.

## References

- Bristol-Myers Squibb-Pfizer. *Eliquis 2.5 mg film-coated tablets—summary of product characteristics*. [www.medicines.org.uk/emc](http://www.medicines.org.uk/emc) (accessed 6 February 2025).
- Boehringer Ingelheim Limited. *Pradaxa 150 mg hard capsules—summary of product characteristics*. [www.medicines.org.uk/emc](http://www.medicines.org.uk/emc) (accessed 6 February 2025).
- Daiichi Sankyo UK Limited. *Lixiana 60mg film-coated tablets—summary of product characteristics*. [www.medicines.org.uk/emc](http://www.medicines.org.uk/emc) (accessed 6 February 2025).
- Bayer plc. *Xarelto 20mg film-coated tablets—summary of product characteristics*. [www.medicines.org.uk/emc](http://www.medicines.org.uk/emc) (accessed 6 February 2025).
- Specialist Pharmacy Service. *DOAC (direct oral anticoagulants) monitoring*. [sps.nhs.uk/monitorings/doacs-direct-oral-anticoagulants-monitoring](https://sps.nhs.uk/monitorings/doacs-direct-oral-anticoagulants-monitoring) (accessed 6 February 2025).
- Primary Care Pharmacy Association, UK Clinical Pharmacy Association, Primary Care Cardiovascular Society. *Anticoagulation for non-valvular atrial fibrillation (NVAf) following NHSE DOAC commissioning recommendations*. UKPCA, 2022.

ABC=age, bodyweight, and creatinine; bd=twice daily; BMI=body mass index; CAD=coronary artery disease; CKD=chronic kidney disease; CrCl=creatinine clearance; DOAC=direct oral anticoagulant; eGFR=estimated glomerular filtration rate; GORD=gastro-oesophageal reflux disease; IT=information technology; MHRA=Medicines and Healthcare products Regulatory Agency; od=once daily; PAD=peripheral arterial disease; PE=pulmonary embolism; VTE=venous thromboembolism.